Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Gold hits record high, heads for best month in 14 years on safe-haven rush
30/09/2025
Asian shares flat ; gold hits record, dollar drops on shutdown fears
30/09/2025
Why is Tata Capital pricing its IPO far below unlisted levels ?
30/09/2025
SBI sees major growth in credit card business as HDFC Bank holds the top spot
30/09/2025
Trump secures Netanyahu's agreement to Gaza deal but Hamas support in question
30/09/2025
10 year bond yield jumps to 1-month high of 6.57%
30/09/2025
